On March 24, 2010
Hey, CEO Pay Can Be Rational: Just Look at Gilead Sciences
If there’s a model for what pharmaceutical company CEO compensation ought to look like, you could do worse than Gilead (GILD)’s John C. Martin. Last year, he got a pay raise of 17 percent, up to about $14.7 million. He
…
0 Comments